Status:
UNKNOWN
Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction
Lead Sponsor:
Shandong Cancer Hospital and Institute
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-70 years
Phase:
PHASE3
Brief Summary
The main clinical goal of NAC is to down-stage the primary tumor for BCS,yet BCS after NAC has been associated with significantly higher ipsilateral breast tumor recurrences.The accuracy of breast tum...
Eligibility Criteria
Inclusion
- Female patients,locally advanced breast cancer,age ≥18 years.
- Histologically confirmed invasive adenocarcinoma of the breast.
- Primary palpable disease confined to a breast and axilla on physical examination. For patients without clinically suspicious axillary adenopathy, the primary tumor must be larger than 2 cm in diameter by physical exam or imaging studies (clinical T2-T3, N0-N1, M0). For patients with clinically suspicious axillary adenopathy, the primary breast tumor can be any size (clinical T1-3, N1-2, M0). (T1N0M0 lesions are excluded.)
- Patients without clearly defined palpable breast mass or axillary lymph nodes but radiographically measurable tumor masses are acceptable. Accepted procedures for measuring breast disease are mammography, MRI, and breast ultrasound. This will need to be re-evaluated after 3 cycles and prior to surgery.
- ECOG 0 or 2
- No distant metastasis, as documented by complete staging workup ≤6 weeks prior to initiation of study treatment.
- No previous treatment for breast cancer.
- Adequate hematologic function with:
- Absolute neutrophil count (ANC) \>1500/μL. Platelets ≥100,000/μL. Hemoglobin ≥10 g/dL.
- Adequate hepatic function with:
- Serum bilirubin ≤ the institutional upper limit of normal (ULN). Aspartate aminotransferase (AST) ≤2.5 x institutional ULN. Alanine aminotransferase (ALT) ≤2.5 x institutional ULN.
- Adequate renal function with serum creatinine ≤1.5 x ULN.
- Planned primary systemic (neoadjuvant) chemotherapy and surgical resection of residual primary tumor (mastectomy or lumpectomy/breast conservation) following completion of neoadjuvant chemotherapy
Exclusion
- inflammatory breast cancer
- Pregnancy or breast-feeding.A negative serum pregnancy test within 7 days prior to first study treatment (Day 1, Cycle 1) for all women of childbearing potential is required. Patients of childbearing potential must agree to use a birth control method that is approved by their study physician while receiving study treatment and for 3 weeks after their last dose of study treatment. Patients must agree to not breast-feed while receiving study treatment.
- Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator (SERM). Patients must have discontinued use of such agents prior to beginning study treatment.
- Uncontrolled intercurrent illness including (but not limited to) ongoing or active infection.
- Concurrent treatment with any anti-cancer therapy other than those agents used in this study.
- Mental condition or psychiatric disorder that would prevent patient comprehension of the nature, scope, and possible consequences of the study or that would limit compliance with study requirements.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2014
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT01917578
Start Date
August 1 2008
End Date
July 1 2014
Last Update
August 6 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shandong Cancer Hospital
Jinan, Shandong, China, 250117